Trials / Recruiting
RecruitingNCT07524348
A Trial to Investigate the Safety of E303 in Participants With Advanced Refractory Solid Tumors
A Phase I, Open-Label, Multi-Center, First-in-Human Trial to Investigate E303, in Participants With Advanced Refractory Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 149 (estimated)
- Sponsor
- Samsung Bioepis Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase I trial to evaluate the safety, tolerability and efficacy of nectin-4 targeting antibody-drug conjugate (SBE303) in participants with advanced solid tumors
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | E303 | All participants will receive an intravenous (IV) infusion of E303 |
Timeline
- Start date
- 2026-03-23
- Primary completion
- 2030-07-01
- Completion
- 2030-07-01
- First posted
- 2026-04-13
- Last updated
- 2026-04-13
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07524348. Inclusion in this directory is not an endorsement.